Figure 5

Antigen spreading and MHC class I loss variant in patient#12. Flow cytometry analyses on serial blood specimen (A) or tumor invaded lymph nodes (B) gating on CD8+ T lymphocytes stained using A2/Mart1 or A2/gag specific fluorescent tetramers. Ex vivo microcultures stimulated with Mart1 peptides and examined according to similar settings. (C) Flow cytometry analyses of two CUR tumor cell lines (pt#12) after the first exosome therapy (continuation treatment) in clinical response and after the second exosome course (second leukapheresis) at relapse for MHC class I (anti-HLA-A2 mAb, anti-HLA-BC mAb and W6.32 Ab) expression. A positive control was included which consisted of a allogeneic HLA-A*0201melanoma line FON.